Evaluation of Efficacy and Safety of AHPL/AYCAP/0114 capsule in Patients Suffering from Erectile Dysfunction - NI

Ari Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male subjects aged 21-50 years suffering from ED for more than 6 months.
•2.Subjects who have scored 11 to 25 on the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) at screening visit.
•3.Subjects should be in an active stable sexual relationship for the entire duration of study
•4.Subjects willing to participate in clinical trial and who have read understood and signed informed consent form.

•1.Subjects having anatomical abnormalities of the penis.
•2.Patients that have undergone radical prostatectomy, spinal cord injury, or any other surgery of urogenital organs.
•3.Patients having unstable angina pectoris, myocardial infarction, stroke, chronic renal and liver diseases, uncontrolled diabetes mellitus and hypertension.
•4.Patients receiving hormonal treatment, antidepressants, antipsychotics, or any other psychoactive drugs.
•5.Subjects having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion.
•6.Known cases of varicocele, hydrocele, HIV/AIDS, Hepatitis C and B, Cancer and major debilitating diseases
•7.Patients receiving corticosteroids and diuretics.
•8.Any major disease that in investigatorâ??s opinion may interfere with male sexual health.
•9.Known hypersensitivity to ingredients used in study drug
•10.Subjects with significant abnormal laboratory parameters
•11.ECG demonstrating any signs of uncontrolled arrhythmia

发起方

Ari Healthcare Pvt Ltd